Bicycle Therapeutics (NASDAQ:BCYC) Upgraded to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC) to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

Several other equities analysts have also recently weighed in on BCYC. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Citizens Jmp set a $12.00 price target on Bicycle Therapeutics in a research report on Friday, October 31st. Truist Financial assumed coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a “hold” rating and a $10.00 price objective on the stock. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.11.

Bicycle Therapeutics Stock Down 0.2%

Shares of BCYC stock opened at $5.23 on Tuesday. Bicycle Therapeutics has a 12 month low of $5.03 and a 12 month high of $13.11. The company’s fifty day simple moving average is $6.56 and its 200-day simple moving average is $7.08. The firm has a market cap of $362.81 million, a PE ratio of -1.44 and a beta of 1.63.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the transaction, the chief executive officer directly owned 618,996 shares of the company’s stock, valued at $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the sale, the chief financial officer owned 87,081 shares of the company’s stock, valued at approximately $565,155.69. This represents a 4.74% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 38,029 shares of company stock worth $251,966. 8.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of large investors have recently made changes to their positions in the company. Assetmark Inc. boosted its stake in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after purchasing an additional 1,552 shares during the period. Clearstead Advisors LLC grew its stake in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after acquiring an additional 3,262 shares in the last quarter. Brooklyn Investment Group acquired a new stake in Bicycle Therapeutics in the 4th quarter worth about $69,000. Ausdal Financial Partners Inc. bought a new stake in Bicycle Therapeutics in the 2nd quarter valued at about $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new position in shares of Bicycle Therapeutics during the 4th quarter worth approximately $71,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.